|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Surgical Neuro-Oncology |
Tri-State Neurosurgical, Inc., Evansville, IN 47710, USA
1 Address correspondence to Eric Goebel, Tri-State Neurosurgical, Inc., 350 West Columbia Street, Suite 350, Evansville, IN 47710, USA (egoebel{at}iupui.edu).
Abstract
While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect. Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers. As a result, one of these individuals had premature death. A brief literature review is provided to assist in explaining the mechanisms by which clinically significant cerebral edema may develop.
References
Brem, H., Mahaley, M.S., Jr., Vick, N.A., Black, K.L., Schold, S.C., Jr., Burger, P.C., Friedman, A.H., Ciric, I.S., Eller, T.W., Cozzens, J.W., and Kenealy, J.N. (1991) Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J. Neurosurg. 74,441 -446.[ISI][Medline]
Brem, H., Tamargo, R.J., Olivi, A., Pinn, M., Weingart, J.D., Wharam, M. and Epstein, J.I. (1994) Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J. Neurosurg. 80,283 -290.[ISI][Medline]
Brem, H., Piantadosi, S., Burger, P.C., Walker, M., Selker, R., Vick, N.A., Black, K., Sisti, M., Brem, S., Mohr, G., Muller, P., Morawetz, R., and Schold, S.C. for the Polymer-Brain Tumor Treatment Group (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345 (8956),1008 -1012.[CrossRef][ISI][Medline]
Dang, W.B., Daviau, T., Ying, P., Zhao, Y., Nowotnik, D., Clow, C.S., Tyler, B., and Brem, H. (1996) Effects of Gliadel wafer initial molecular weight on the erosion of wafer and release of BCNU. J. Control. Release 42(1),83 -92.[CrossRef]
Fleming, A.B., and Saltzman, W.M. (2002) Pharmacokinetics of the carmustine implant. Clin. Pharmacokinet. 41,403 -419.[CrossRef][ISI][Medline]
Fung, L.K., Shin, M., Tyler, B., Brem, H., and Saltzman, W.M. (1996) Chemotherapeutic drugs released from polymers: Distribution of 1,3-bis (2-chloroethyl)-1-nitrosourea in the rat brain. Pharm. Res. 13,671 -682.[CrossRef][ISI][Medline]
Giese, A., and Westphal, M. (1996) Glioma invasion in the central nervous system. Neurosurgery 39,235 -250.[CrossRef][ISI][Medline]
Grossman, S.A., Reinhard, C., Colvin, O.M., Chasin, M., Brundrett, R., Tamargo, R.J., and Brem, H. (1992) The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J. Neurosurg. 76,640 -647.[ISI][Medline]
Olivi, A., Grossman, S.A., Tatter, S., Barker, F., Judy, K., Olsen,
J., Bruce, J., Hilt, D., Fisher, J., and Piantadosi, S. (2003)
Dose escalation of carmustine in surgically implanted polymers in patients
with recurrent malignant glioma: A New Approaches to Brain Tumor Therapy CNS
Consortium trial. J. Clin. Oncol.
21,1845
-1849.
Reulen, H.J., Graham, R., Spatz, M., and Klatzo, I. (1977) Role of pressure gradients and bulk flow in dynamics of vasogenic brain edema. J. Neurosurg. 46, 24-35.[ISI][Medline]
Subach, B.R., Witham, T.F., Kondziolka, D., Lunsford, L.D., Bozik, M., and Schiff, D. (1999) Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: A retrospective case-matched cohort series. Neurosurgery 45,17 -22.[CrossRef][ISI][Medline]
Valtonen, S., Timonen, U., Toivanen, P., Kalimo, H., Kivipelto, L., Heiskanen, O., Unsqaard, G., and Kuurne, T. (1997) Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study. Neurosurgery 41, 48-49.
Westphal, M., Hilt, D.C., Bortey, E., Delavault, P., Olivares, R., Warnke, P.C., Whittle, I.R., Jaaskelainen, J., and Ram, Z. (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncol. 5,79 -88.[Abstract]
This article has been cited by other articles:
|
|
 |
|
  F. J. Attenello, D. Mukherjee, G. Datoo, M. J. McGirt, E. Bohan, J. D. Weingart, A. Olivi, A. Quinones-Hinojosa, and H. Brem Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience Ann. Surg. Oncol., October 1, 2008; 15(10): 2887 - 2893. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
